there is no major difference

This study has some level of methodological limitations, therefore, more high-quality large-scale clinical randomized
controlled trials are still needed to better guide decision
making on this clinical practice.

In this way

we did not find significant heterogeneity
between summary estimates from observational studies and RCTs, this bias has little chance of changing
the overall conclusions of this analysis.

However, to confirm this finding, further data are needed from
studies that use simultaneous adjustment for important confounders.

To directly test for an association between
HLA-B*13:01 and the dapsone hypersensitivity
syndrome as well as to assess the accuracy of the
HLA imputation, we determined the HLA-B and
HLA-C alleles in the 39 case patients and 78 controls included in the discovery analysis and an
additional 38 case patients and 206 controls, using
Roche 454 GS FLX sequencing.

but was not found to
significantly
with no evidence of genetic heterogeneity between the discovery and replication samples
The findings
The strong genetic effect

However, to confirm this finding, further data are needed from
studies that use simultaneous adjustment for important confounders.
Currently,no tests are available to predict the risk of the dapsone hypersensitivity syndrome.

What is more, the length of
the follow‑up phase is different. There was a need for more
research in which the effect of the two therapies at follow‑up
will be compared.

. Future research should be conducted with low
risk of bias, more kinds of outcome measures, more standard
intervention and longer follow‑up

it is not sufficiently compelling

enzymatic activity

At present, there is an insufficient evidentiary basis to recommend routine CYP2D6 genotyping to
guide tamoxifen therapy, a conclusion consistent with the
current adjuvant therapy guidelines (6, 8, 29).